Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NESCIO neoadjuvant immunotherapy trial in high-risk clear cell renal cell carcinoma
NL-OMON58670Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Nivolumab monotherapy with Nivolumab + relatlimab (2 arms). Primary endpoint: Pathologic response rate. Started Jan 2022; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON58670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58670.